menu

Medical Program: Are PARP Inhibitors the Future of Treating Triple-Negative Breast Cancer?

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Are PARP Inhibitors the Future of Treating Triple-Negative Breast Cancer?

Are PARP Inhibitors the Future of Treating Triple-Negative Breast Cancer?
RestartResume
Chemotherapy used to be the only option for patients with primary triple-negative breast cancer, but now there are targeted agents on the horizon.
  • Sponsored by

  • Overview

    At the 2019 European Society for Medical Oncology (ESMO) Congress in Barcelona, Spain, Dr. Matt Birnholz got a chance to talk with Dr. Hans Petter Eikesdal about the head-turning study on PARP inhibitors he presented at the conference.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 12/14/19